Immunology
FDA clears IGM Biosciences’ INDs for SLE and RA therapy trials
The US Food and Drug Administration (FDA) has cleared IGM Biosciences’ two investigational new drug (IND) applications for initiating Phase…
Xencor reports data from Phase Ia study of XmAb564 in healthy volunteers
Xencor has reported clinical results from a Phase Ia single-ascending dose study of XmAb564, a monovalent Interleukin-2 (IL-2) Fc fusion…
Abbvie’s Rinvoq grabs secondary endpoints in Phase II SLE trial
Abbvie has announced secondary endpoint data from a Phase II trial investigating Rinvoq (upadacitinib) in adults with moderately to severely…
Hansa starts dosing in Phase III trial in anti-GBM disease
Hansa Biopharma has dosed the first patient in a pivotal Phase III trial investigating imlifidase in patients with anti-glomerular basement…
Pipeline Moves: Novo Nordisk Phase III semaglutide completion bumps approval prospects
This week on Pipeline Moves, we start the week by looking at the completion of the Phase III trial investigating…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Topas launches Phase IIa trial of celiac disease therapy
Topas Therapeutics has launched a Phase IIa clinical trial of TPM502 to treat patients with celiac disease, an autoimmune disorder.…
ASLAN doses first subject in alopecia areata therapy trial
Singapore-based pharmaceutical company ASLAN Pharmaceuticals has dosed the first patient in a Phase IIa trial of farudodstat. Farudodstat is indicated…
DRAP approves YS Biopharma’s Phase III rabies vaccine trial in Pakistan
The Drug Regulatory Authority of Pakistan (DRAP) has granted approval to YS Biopharma to initiate a Phase III clinical trial…
Leading innovators in genetically modified T-cells for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,…
Leading innovators in attenuated virus-based vaccines
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,…